Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2011 by AHS Cancer Control Alberta.
Recruitment status was  Recruiting
Information provided by:
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
First received: September 8, 2005
Last updated: January 18, 2012
Last verified: September 2011
A study of pharmacokinetics of daily intravenous busulfan

Condition Intervention
Hematologic Malignancy
Drug: intravenous busulfan

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell

Resource links provided by NLM:

Further study details as provided by AHS Cancer Control Alberta:

Primary Outcome Measures:
  • pharmacokinetic data

Estimated Enrollment: 200
Study Start Date: January 1998
Estimated Study Completion Date: December 2010
Detailed Description:
A study of pharmacokinetics of daily intravenous busulfan

Ages Eligible for Study:   up to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients undergoing transplantation

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00156858

Canada, Alberta
Tom Baker Cancer Centre Recruiting
Calgary, Alberta, Canada, T2N 4N2
Contact: Rachel Syme, PhD       clinical_trials_tbcc@cancerboard.ab.ca   
Sub-Investigator: Chris Brown         
Sub-Investigator: Ron Anderson         
Principal Investigator: James Russell         
Sub-Investigator: Victor Lewis         
Sponsors and Collaborators
Alberta Health Services
Principal Investigator: James Russell, FRCp Alberta Cancerboard
  More Information

ClinicalTrials.gov Identifier: NCT00156858     History of Changes
Other Study ID Numbers: 10156  717905172 
Study First Received: September 8, 2005
Last Updated: January 18, 2012
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:

Additional relevant MeSH terms:
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 30, 2016